Biogen Licenses Parkinson’s Drug from Alectos Therapeutics for up to US$722.5 M
By Ashish Tripathi
Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)
Published: 14 Jun-2022
DOI: 10.3833/pdr.v2022.i6.2696 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to bolster its pipeline, Biogen has partnered with Alectos Therapeutics to develop and commercialise glucocerebrosidase 2 (GBA2) inhibitors...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS